Targeted Therapies in Oncology Staff

A 72-year-old White man presented with chest pain, cough, and dyspnea. He had a medical history of type 1 diabetes that was adequately controlled, and was a former smoker.

During an interview, Yi-Bin Chen, MD, an investigator of the REACH trials, discussed acute and chronic graft-versus-host disease and treatment options.

Data continue to support the use of RET inhibitors is patients with RET fusion-positive non–small cell lung cancer.

Following the FDA approval of sotorasib for the treatment of KRAS G12C-positive non–small cell lung cancer, there is a great deal of interest in the KRAS inhibitor and its potential benefit.

When findings of larotrectinib, a pan-TRK inhibitor co-developed by Bayer and Loxo Oncology, that generated significant excitement for the treatment of both adult and pediatric patients with TRK fusion cancers, were presented during the 2017 ASCO Annual Meeting, the small molecule was lauded as a future standard of care for patients with advanced solid tumors harboring a TRK fusion.